Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Prospective multi-country, real-world, multi-arm study of treatment PErsistence with RISankizumab in Psoriatic Arthritis	AbbVie / Ray	Ongoing	Risankizumab (Skyrizi®)	4	P24-390	King Fahad Medical City (Riyadh)
An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis with Moderate-to-Severe Pruritus	Vifor Pharma, Inc. / Balsam	Ongoing	Difelikefalin	2	KOR-PED-202	King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah)
A Phase 2 / Phase 3, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Adaptive Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis	CSL Behring LLC	Ongoing	CSL889	3	CSL889_2001	King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh), Prince Mohammad Bin Naser Hospital (Jazan)
Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial)	PI initiative	Ongoing	Sodium Chloride / Lactated Ringers	4	FLASC01	King Fahad University Hospital (Al-Khobar)
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study To Assess The Efficacy And Safety of Induction and Maintenance Therapy with Ro7790121 in Patients with Moderately to Severely Active Crohn's Disease	Roche / IQVIA	Ongoing	Ro7790121	3	GA45331	King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh)
A randomized, double-blinded placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of Efgartigimod PH20 SC Administered by prefilled syringe in adults participants with ocular MG	Argenx BV / Balsam	Ongoing	Efgartigimod	3	ARGX-113-2315	King Faisal Specialist Hospital and Research Center (Riyadh)
Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies	AstraZeneca/ IQVIA	Ongoing	Eculizumab	3	ALXN-MG-50	Aseer Hospital (Abha), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease	Argenx BV / IQVIA	Ongoing	Efgartigimod	3	ARGX-113-2306	King Faisal Specialist Hospital and Research Center (Riyadh) , King Khalid University Hospital (Riyadh)
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)	Novartis	Ongoing	Rapcabtagene Autoleucel (YTB323)	2	CYTB323I12201	King Faisal Specialist Hospital and Research Center (Riyadh)
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)	GB002, Inc / Balsam	Ongoing	Seralutinib	3	GB002-3102	King Faisal Specialist Hospital and Research Center (Riyadh) , King Fahad Medical City (Riyadh)